Andrew H Ko
Overview
Explore the profile of Andrew H Ko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
6406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ko A, Chao J, Noel M, Shankaran V, Sohal D, Crow M, et al.
Cancer Res Commun
. 2025 Feb;
5(2):349-357.
PMID: 39907035
Purpose: Neoadjuvant chemoradiation (NCRT) followed by surgical resection represents a standard approach for patients with locally advanced esophageal/gastroesophageal junction (GEJ) cancers. Sotigalimab is a high-affinity CD40 agonist antibody capable of...
2.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J, et al.
Nat Med
. 2025 Jan;
PMID: 39833408
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T...
3.
Ko A, Oh D, Lau J, Mhatre S, Ci B, Machado R, et al.
Clin Pharmacol Ther
. 2024 Dec;
PMID: 39707623
Enrolling adequate numbers of patients into the control arm of randomized controlled trials (RCTs) often presents barriers. There is interest in leveraging real-world data (RWD) from electronic health records (EHRs)...
4.
Cloyd J, Sarna A, Arango M, Bates S, Bhutani M, Bloomston M, et al.
JAMA Surg
. 2024 Dec;
160(2):172-180.
PMID: 39630427
Importance: Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and...
5.
Till J, McDaniel L, Chang C, Long Q, Pfeiffer S, Lyman J, et al.
Nat Commun
. 2024 Jul;
15(1):5763.
PMID: 38982051
While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here...
6.
Miller P, Romero-Hernandez F, Calthorpe L, Wang J, Kim S, Corvera C, et al.
Ann Surg Oncol
. 2024 Jun;
31(9):6147-6156.
PMID: 38879670
Background: In 2023 alone, it's estimated that over 64,000 patients will be diagnosed with PDAC and more than 50,000 patients will die of the disease. Current guidelines recommend neoadjuvant therapy...
7.
Tsang E, Dhawan M, Pacaud R, Thomas S, Grabowsky J, Wilch L, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300494.
PMID: 38865673
Purpose: Combining poly ADP-ribose polymerase (PARP) and topoisomerase I inhibitors has demonstrated synergistic effects in in vivo models. This phase I trial evaluated rucaparib and irinotecan in metastatic solid tumors...
8.
Ko A, Coveler A, Schlechter B, Bekaii-Saab T, Wolpin B, Clark J, et al.
Invest New Drugs
. 2024 Mar;
42(2):221-228.
PMID: 38441850
AbGn-107 is an antibody-drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-107 in both...
9.
OReilly E, Ko A, Friedberg J
J Clin Oncol
. 2023 Dec;
41(36):5479-5480.
PMID: 38100990
No abstract available.
10.
Gordon J, Chen H, Nickles T, Lee P, Bok R, Ohliger M, et al.
J Magn Reson Imaging
. 2023 Dec;
60(2):741-749.
PMID: 38041836
Background: Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States. However, early response assessment using the current approach of measuring changes in tumor...